ClinicalTrials.gg
TerminatedNCT01284348Updated Aug 29, 2024Results posted

To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer

A Phase 2 interventional study of Sotatercept 15 mg and Sotatercept 30 mg in Anemia, Carcinoma, Non-Small-Cell Lung and Carcinoma, Small-Cell Lung, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-29.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Supportive care

Why this study was terminated
Persistent low enrollment made study continuation no longer feasible

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study was to determine an effective and safe dose of sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia (CIA) in participants with metastatic non-small cell lung cancer (NSCLC) who are being treated with first-line platinum based chemotherapy.

Read the detailed description

The ACE-011-NSCL-001 Phase 2a study was an open-label, randomized, dose-ranging study designed to assess the efficacy, safety, tolerability, pharmacokinetic and quality of life of sotatercept for treatment of CIA in participants with advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens. Other objectives included the effect of sotatercept treatment on bone metabolism, the evaluation of the expression of Activin A and other proteins/biomarkers (including myostatin and follistatin) and the assessment of renal function biomarkers. The study consisted of a Screening Period, a Treatment Period of approximately 6 months (up to 4 doses of sotatercept at either 15 mg or 30 mg administered subcutaneously every 42 days) and a Post-treatment Follow-up Period or End of Treatment (42 days after the last dose of sotatercept). The study was terminated early due to a slower than expected rate of enrollment as a result of substantial changes in the standard of care for cancer participants with anemia which resulted in challenges to timely accrual and completion of the study. Therefore, 26 participants were randomized into the study and the planned Part 2 of the study consisting of a double-blind, randomized, placebo-controlled Phase 2b/3 study conducted at the optimal dose of sotatercept in up to 750 participants with metastatic NSCLC was not performed. Due to the small sample size and variability of the data, changes were made to modify the study endpoints and revise them to be exploratory only.

02

Conditions studied

  • Anemia
  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma, Small-Cell Lung
  • Bladder Cancer
  • Cancer of Head and Neck
  • Uterine Cervical Cancer

Keywords

  • Chemotherapy induced anemia
  • Non-small cell lung cancer
03

In context

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

This study's enrollment of 26 is below the median of 117 across 1,336 interventional studies indexed under Anemia.

Browse Anemia studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women >18 years of age
  2. Part 1: confirmed (cytology or ) solid tumor , excluding those solid tumors treated with curative intent.

    Part 2: Histologically confirmed non-small cell lung cancer

  3. Documented disease
  4. Measurable or non- evaluable by (RECIST) Version 1.1
  5. All of the following laboratory values:

    • ≥6.5 to \<11.0 g/dL (≥65 to \<110 g/L), due to chemotherapy-induced anemia
    • ≥500/mm\^3
    • count ≥75,000/mm\^3 (>2 hours since prior platelet transfusion
    • Adequate renal function

      • ≥40mL/min or ≥50 mL/min if cisplatin is concomitantly administered and
      • urine protein / creatinine ratio ≤1.0; or ≤2.0 if bevacizumab (Avastin®) is concomitantly administered
    • Hepatic function ( \<1.5 x (ULN); and ALT \<3.0 x ULN and ≤5.0 ULN for participants with liver metastases)
  6. Participants must have received:

    • at least one cycle and up to 4 cycles (q3w schedule) of platinum-based chemotherapy and be randomized prior to receiving Cycle 5 OR
    • at least one cycle and up to 3 months (depending upon regimen) of platinum-based chemotherapy
  7. >28 days since previous treatment with ESA
  8. >14 days since last red blood cell transfusions
  9. Eastern Oncology Cooperative Group () Performance status 0-2
  10. For females of , highly effective method of for at least 28 days before starting study, during participation and at least 112 days following last dose of sotatercept
  11. Males must use latex condom or non-latex condom not made of (animal) membrane during any sexual contact with female of childbearing potential
  12. of >3 months
  13. Willing to adhere to study visit schedule
  14. Understand and voluntarily sign

Exclusion criteria

Exclusion Criteria:

Part 2 only, history of prior regimen(s)of platinum-based chemotherapy for NSCLC and/or history of platinum-based chemotherapy with last dose received less than six months prior to the start of current platinum-based chemotherapy for metastatic NSCLC.

  1. National Cancer Institute Common Terminology for Adverse Events Grade >3 toxicity
  2. Prior radiation to >20% of whole skeleton
  3. Prior regimen(s) of platinum based chemotherapy for metastatic disease and/or history of adjuvant platinum-based chemotherapy with the last dose received less than six months prior to the start of current first-line platinum-based chemotherapy for metastatic disease
  4. Central nervous system metastases
  5. pulmonary, endocrine, neurologic, gastrointestinal, hepatic, or genitourinary disease unrelated to underlying
  6. Classification of 3 or higher heart failure (as classified by )
  7. History of thrombosis, deep vein thrombosis, pulmonary emboli, or embolic stroke, if not stable on anticoagulants and/or one of these events occurring in past 6 months
  8. Diagnosis of a myeloid malignancy or known history of myelodysplasia
  9. Recent history (within 14 days of Day 1) of IV/oral antibiotics due to post septic episode
  10. Uncontrolled hypertension. Controlled hypertension is considered clinically stable, and systolic blood pressure (SBP) must be \<150 mmHg and diastolic blood pressure (DBP) must be \< 00 mmHg.
  11. Known (HIV)
  12. Known active or C antibody
  13. Iron deficiency
  14. History of anemia as a result of inherited hemoglobinopathy
  15. History of anemia due to or hereditary hemolysis or gastrointestinal bleeding
  16. Received treatment with another drug or device within 28 days prior to Day 1, or if the half life of the previous product is known, within 5 times the half life prior to dosing, whichever may be longer.
  17. Any prior use of sotatercept.
  18. Pregnant or lactating females or females planning to become pregnant
  19. History of severe allergic or anaphylactic reactions or to recombinant proteins or in the investigational product (Refer to the Investigator's Brochure for further information).
  20. Major surgery within 30 days prior to Day 1 (participants must have completely recovered from any previous surgery prior to Day 1).
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Sotatercept 15 mg

    Participants will receive sotatercept 15 mg by subcutaneous (SC) injection once every 42 days, up to four doses.

    Drug: Sotatercept 15 mg

  • Experimental
    Sotatercept 30 mg

    Participants will receive sotatercept 30 mg by SC injection once every 42 days, up to four doses.

    Drug: Sotatercept 30 mg

Interventions

  • Sotatercept 15 mg SC injection once every 42 days, up to four doses

    Also known as: ACE-011

  • Sotatercept 30 mg SC injection once every 42 days, up to four doses

    Also known as: ACE-011

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced a Hematopoietic Response

    A hematopoietic response was defined as an increase in a participant's hemoglobin (Hgb) of ≥1.0 g/dL above the study baseline value for 4 consecutive weeks, in the absence of red blood cell transfusion and/or erythropoiesis-stimulating agents.

    Time frame: Up to Day 28

Secondary outcomes

  1. Number of Participants Who Experienced One or More Adverse Events (AEs)

    An AE is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.

    Time frame: Up to approximately 6 months

  2. Time to Progression (TTP)

    TTP was defined as the time from date of randomization to date of diagnosis of progressive disease

    Time frame: Up to 6 months

  3. Progression Free Survival (PFS)

    PFS was defined as the time from the start of study drug therapy to the first observation of disease progression or death due to any cause, whichever came first

    Time frame: Up to 12 months

  4. Overall Survival (OS)

    OS was defined as the time between randomization and death

    Time frame: Up to 24 months

  5. Overall Response Rate (ORR)

    Overall Response was defined as the percentage of participants who achieved an objective confirmed complete (CR) or partial response (PR). Response was determined according to Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1 guidelines. CR: The disappearance of all known disease and no new sites or disease-related symptoms confirmed at least 4 weeks after initial documentation. All sites must be assessed, including non-measurable sites, such as effusions, or markers. PR: At least a 30% decrease in the sum of the longest diameters of target lesions, taking as a reference the baseline sum of the longest diameters confirmed at least 4 weeks after initial documentation and no new non-target lesions and/or unequivocal progression of existing non-target lesions. PR is also recorded when all measurable disease has completely disappeared, but a non-measurable component (i.e., ascites) is still present but not progressing.

    Time frame: Up to 12 months

  6. Number of Participants Who Experienced an Improvement in Quality of Life Scores

    Participants were to be assessed on improvement of quality of life using the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale (Version 4.0) and the Lung Cancer Symptom Scale (LCSS). The FACIT Fatigue score ranges from 0 to 52, with 0 representing the best outcome and 52 representing the worst outcome. The LCSS is a 9-item patient-rated scale, 6 of which measure major symptoms (loss of appetite, fatigue, cough, dyspnoea, pain, and haemoptysis), and 3 of which are summation items related to total symptomatic distress, activity, and overall quality of life. Participants responses are measured using the mean score on the 9-item visual analogue scales, with 100-mm lines, with 0 representing the best outcome and 100 representing the worst outcome.

    Time frame: Up to 6 months

  7. Area Under the Concentration Versus Time Curve From Time 0 to 28 Days (AUC0-28d) of Sotatercept Following a Single Dose

    AUC0-28d is a measure of the mean concentration levels of a drug in the plasma from time 0 to 28 days.

    Time frame: Pre-dose 1 Day 1, 4 hours post-dose Day 1, Day 5, Day 8, Day 11, Day 15, Day 22, Day 28

  8. Area Under the Concentration Versus Time Curve From Time 0 to Infinity (AUC0-inf) of Sotatercept Following a Single Dose

    AUC0-inf is the area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time.

    Time frame: Pre-dose 1 Day 1, 4 hours post-dose Day 1, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 36, pre-dose 2 Day 43

  9. Maximum Plasma Concentration (Cmax) of Sotatercept Following a Single Dose

    Cmax is a measure of the maximum amount of drug in the plasma after a dose is given.

    Time frame: Pre-dose 1 Day 1, 4 hours post-dose Day 1, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 36, pre-dose 2 Day 43

  10. Time to Maximum Concetration (Tmax) of Sotatercept Following a Single Dose

    Tmax is a measure of the time it takes for a drug to reach maximum concentration in the plasma after the dose is given.

    Time frame: Pre-dose 1 Day 1, 4 hours post-dose Day 1, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 36, pre-dose 2 Day 43

  11. Apparent Terminal Half-life (t1/2) of Sotatercept Following a Single Dose

    t1/2 is the elimination half-life of study drug: the time it takes for half of the study drug in the blood plasma to dissipate.

    Time frame: Pre-dose 1 Day 1, 4 hours post-dose Day 1, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 36, pre-dose 2 Day 43

  12. Apparent Serum Clearance (CL/F) of Sotatercept Following a Single Dose

    Apparent serum CL is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.

    Time frame: Pre-dose 1 Day 1, 4 hours post-dose Day 1, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 36, pre-dose 2 Day 43

  13. Apparent Volume of Distribution (Vz/F) Following a Single Dose of Sotatercept

    Vz/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.

    Time frame: Pre-dose 1 Day 1, 4 hours post-dose Day 1, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 36, pre-dose 2 Day 43

07

Results

Posted Oct 31, 2023

Participant flow

Participant flow — Overall Study
MilestoneSotatercept 15 mgSotatercept 30 mg
Started1412
Treated1411
Completed40
Not completed1012
Withdrew: Death11
Withdrew: Withdrew consent01
Withdrew: Status not recorded910

Outcome measures

PrimaryNumber of Participants Who Experienced a Hematopoietic Response

A hematopoietic response was defined as an increase in a participant's hemoglobin (Hgb) of ≥1.0 g/dL above the study baseline value for 4 consecutive weeks, in the absence of red blood cell transfusion and/or erythropoiesis-stimulating agents.

Time frame:
Up to Day 28
Reported as:
Count of participants · Participants
Number of Participants Who Experienced a Hematopoietic Response
ParticipantsSotatercept 15 mgSotatercept 30 mg
Number of Participants Who Experienced a Hematopoietic Response22
SecondaryNumber of Participants Who Experienced One or More Adverse Events (AEs)

An AE is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.

Time frame:
Up to approximately 6 months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced One or More Adverse Events (AEs)
ParticipantsSotatercept 15 mgSotatercept 30 mg
Number of Participants Who Experienced One or More Adverse Events (AEs)1410
SecondaryTime to Progression (TTP)

TTP was defined as the time from date of randomization to date of diagnosis of progressive disease

Time frame:
Up to 6 months

No measurements were reported for this outcome.

SecondaryProgression Free Survival (PFS)

PFS was defined as the time from the start of study drug therapy to the first observation of disease progression or death due to any cause, whichever came first

Time frame:
Up to 12 months

No measurements were reported for this outcome.

SecondaryOverall Survival (OS)

OS was defined as the time between randomization and death

Time frame:
Up to 24 months

No measurements were reported for this outcome.

SecondaryOverall Response Rate (ORR)

Overall Response was defined as the percentage of participants who achieved an objective confirmed complete (CR) or partial response (PR). Response was determined according to Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1 guidelines. CR: The disappearance of all known disease and no new sites or disease-related symptoms confirmed at least 4 weeks after initial documentation. All sites must be assessed, including non-measurable sites, such as effusions, or markers. PR: At least a 30% decrease in the sum of the longest diameters of target lesions, taking as a reference the baseline sum of the longest diameters confirmed at least 4 weeks after initial documentation and no new non-target lesions and/or unequivocal progression of existing non-target lesions. PR is also recorded when all measurable disease has completely disappeared, but a non-measurable component (i.e., ascites) is still present but not progressing.

Time frame:
Up to 12 months

No measurements were reported for this outcome.

SecondaryNumber of Participants Who Experienced an Improvement in Quality of Life Scores

Participants were to be assessed on improvement of quality of life using the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale (Version 4.0) and the Lung Cancer Symptom Scale (LCSS). The FACIT Fatigue score ranges from 0 to 52, with 0 representing the best outcome and 52 representing the worst outcome. The LCSS is a 9-item patient-rated scale, 6 of which measure major symptoms (loss of appetite, fatigue, cough, dyspnoea, pain, and haemoptysis), and 3 of which are summation items related to total symptomatic distress, activity, and overall quality of life. Participants responses are measured using the mean score on the 9-item visual analogue scales, with 100-mm lines, with 0 representing the best outcome and 100 representing the worst outcome.

Time frame:
Up to 6 months

No measurements were reported for this outcome.

SecondaryArea Under the Concentration Versus Time Curve From Time 0 to 28 Days (AUC0-28d) of Sotatercept Following a Single Dose

AUC0-28d is a measure of the mean concentration levels of a drug in the plasma from time 0 to 28 days.

Time frame:
Pre-dose 1 Day 1, 4 hours post-dose Day 1, Day 5, Day 8, Day 11, Day 15, Day 22, Day 28
Reported as:
Mean · day*ng/mL
Area Under the Concentration Versus Time Curve From Time 0 to 28 Days (AUC0-28d) of Sotatercept Following a Single Dose
day*ng/mLSotatercept 15 mgSotatercept 30 mg
Area Under the Concentration Versus Time Curve From Time 0 to 28 Days (AUC0-28d) of Sotatercept Following a Single Dose24443.28 ± 8130.5243977.03 ± 18490.17
SecondaryArea Under the Concentration Versus Time Curve From Time 0 to Infinity (AUC0-inf) of Sotatercept Following a Single Dose

AUC0-inf is the area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time.

Time frame:
Pre-dose 1 Day 1, 4 hours post-dose Day 1, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 36, pre-dose 2 Day 43
Reported as:
Mean · day*ng/mL
Area Under the Concentration Versus Time Curve From Time 0 to Infinity (AUC0-inf) of Sotatercept Following a Single Dose
day*ng/mLSotatercept 15 mgSotatercept 30 mg
Area Under the Concentration Versus Time Curve From Time 0 to Infinity (AUC0-inf) of Sotatercept Following a Single Dose40145.34 ± 20680.76137994.6 ± 18183.66
SecondaryMaximum Plasma Concentration (Cmax) of Sotatercept Following a Single Dose

Cmax is a measure of the maximum amount of drug in the plasma after a dose is given.

Time frame:
Pre-dose 1 Day 1, 4 hours post-dose Day 1, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 36, pre-dose 2 Day 43
Reported as:
Mean · ng/mL
Maximum Plasma Concentration (Cmax) of Sotatercept Following a Single Dose
ng/mLSotatercept 15 mgSotatercept 30 mg
Maximum Plasma Concentration (Cmax) of Sotatercept Following a Single Dose1325.33 ± 435.892069.68 ± 842.43
SecondaryTime to Maximum Concetration (Tmax) of Sotatercept Following a Single Dose

Tmax is a measure of the time it takes for a drug to reach maximum concentration in the plasma after the dose is given.

Time frame:
Pre-dose 1 Day 1, 4 hours post-dose Day 1, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 36, pre-dose 2 Day 43
Reported as:
Mean · Days
Time to Maximum Concetration (Tmax) of Sotatercept Following a Single Dose
DaysSotatercept 15 mgSotatercept 30 mg
Time to Maximum Concetration (Tmax) of Sotatercept Following a Single Dose8.16 ± 3.7812.31 ± 7.67
SecondaryApparent Terminal Half-life (t1/2) of Sotatercept Following a Single Dose

t1/2 is the elimination half-life of study drug: the time it takes for half of the study drug in the blood plasma to dissipate.

Time frame:
Pre-dose 1 Day 1, 4 hours post-dose Day 1, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 36, pre-dose 2 Day 43
Reported as:
Mean · Days
Apparent Terminal Half-life (t1/2) of Sotatercept Following a Single Dose
DaysSotatercept 15 mgSotatercept 30 mg
Apparent Terminal Half-life (t1/2) of Sotatercept Following a Single Dose18.98 ± 7.9630.84 ± 9.46
SecondaryApparent Serum Clearance (CL/F) of Sotatercept Following a Single Dose

Apparent serum CL is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.

Time frame:
Pre-dose 1 Day 1, 4 hours post-dose Day 1, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 36, pre-dose 2 Day 43
Reported as:
Mean · mL/day
Apparent Serum Clearance (CL/F) of Sotatercept Following a Single Dose
mL/daySotatercept 15 mgSotatercept 30 mg
Apparent Serum Clearance (CL/F) of Sotatercept Following a Single Dose479.36 ± 254.44220.14 ± 31.17
SecondaryApparent Volume of Distribution (Vz/F) Following a Single Dose of Sotatercept

Vz/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.

Time frame:
Pre-dose 1 Day 1, 4 hours post-dose Day 1, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 36, pre-dose 2 Day 43
Reported as:
Mean · mL
Apparent Volume of Distribution (Vz/F) Following a Single Dose of Sotatercept
mLSotatercept 15 mgSotatercept 30 mg
Apparent Volume of Distribution (Vz/F) Following a Single Dose of Sotatercept11944.60 ± 7172.849849.80 ± 3449.33

Adverse events

Collected over Up to approximately 6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sotatercept 15 mg6/14 (42.9%)4/14 (28.6%)14/14 (100%)
Sotatercept 30 mg5/12 (41.7%)8/11 (72.7%)10/11 (90.9%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventSotatercept 15 mgSotatercept 30 mg
ThrombocytopeniaBlood and lymphatic system disorders0/144/11
AnaemiaBlood and lymphatic system disorders0/142/11
Febrile neutropeniaBlood and lymphatic system disorders0/142/11
Non-small cell lung cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/142/11
Atrial fibrillationCardiac disorders0/141/11
Gastrointestinal haemorrhageGastrointestinal disorders0/141/11
AstheniaGeneral disorders0/141/11
DeathGeneral disorders0/141/11
PneumoniaInfections and infestations0/141/11
SepsisInfections and infestations0/141/11
Most frequent other events
Showing 10 of 126
Most frequent other events
EventSotatercept 15 mgSotatercept 30 mg
AnaemiaBlood and lymphatic system disorders4/146/11
FatigueGeneral disorders7/144/11
ThrombocytopeniaBlood and lymphatic system disorders3/145/11
NauseaGastrointestinal disorders6/141/11
NeutropeniaBlood and lymphatic system disorders3/144/11
Oedema peripheralGeneral disorders4/144/11
HyperglycaemiaMetabolism and nutrition disorders4/144/11
HypokalaemiaMetabolism and nutrition disorders1/144/11
DyspnoeaRespiratory, thoracic and mediastinal disorders3/144/11
VomitingGastrointestinal disorders5/140/11

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Sotatercept 15 mgSotatercept 30 mgTotal
Mean61.4 ± 14.168.5 ± 9.164.7 ± 12.3
Sex: Female, Male
Sex: Female, Male(Participants)Sotatercept 15 mgSotatercept 30 mgTotal
Female8614
Male6612
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sotatercept 15 mgSotatercept 30 mgTotal
Hispanic or Latino000
Not Hispanic or Latino141125
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sotatercept 15 mgSotatercept 30 mgTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American101
White131124
More than one race000
Unknown or Not Reported000
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Raftopoulos H, Laadem A, Hesketh PJ, Goldschmidt J, Gabrail N, Osborne C, Ali M, Sherman ML, Wang D, Glaspy JA, Puccio-Pick M, Zou J, Crawford J. Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies. Support Care Cancer. 2016 Apr;24(4):1517-25. doi: 10.1007/s00520-015-2929-9. Epub 2015 Sep 14. PubMed 26370220 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2011 to primary completion in Sep 2012, 17 months.

Results were first posted in Oct 2023, 11 years 1 month after primary completion. A results delay was requested in Aug 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2010
First posted
Jan 27, 2011
StartActual
Mar 25, 2011
Primary completionActual
Sep 21, 2012
CompletionActual
Sep 21, 2012
Results delay requested
Aug 21, 2014
Results first posted
Oct 31, 2023
Last update
Aug 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01284348
Responsible party
Sponsor
First posted
Jan 27, 2011
Start date
Mar 25, 2011
Primary completion
Sep 21, 2012
Completion
Sep 21, 2012
Results posted
Oct 31, 2023
Last update
Aug 29, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sotatercept

Start the discussion